<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088998</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N0432</org_study_id>
    <secondary_id>NCI-2012-02617</secondary_id>
    <secondary_id>CDR0000377886</secondary_id>
    <nct_id>NCT00088998</nct_id>
  </id_info>
  <brief_title>Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies&#xD;
      such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing&#xD;
      substances to them without harming normal cells. Bevacizumab may also stop the growth of&#xD;
      tumor cells by stopping blood flow to the tumor. Combining chemotherapy with monoclonal&#xD;
      antibody therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving docetaxel and capecitabine together&#xD;
      with bevacizumab works in treating patients with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with metastatic breast cancer treated with&#xD;
           docetaxel, capecitabine, and bevacizumab as first-line chemotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine time to disease progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1.&#xD;
      Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21&#xD;
      days in the absence of disease progression or unacceptable toxicity. Patients achieving a&#xD;
      complete response (CR) receive at least 2 additional courses beyond CR.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually&#xD;
      for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed tumor response (complete or partial) rate as measured by RECIST</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>docetaxel + bevacizumab + capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.&#xD;
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>docetaxel + bevacizumab + capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>docetaxel + bevacizumab + capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>docetaxel + bevacizumab + capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Clinical evidence of metastatic disease&#xD;
&#xD;
                    -  No bone metastases as the only evidence of metastasis&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 lesion ≥ 2.0 cm by CT scan or MRI OR ≥ 1.0 cm by spiral CT scan&#xD;
&#xD;
                    -  Lesions on chest x-ray allowed provided they are clearly defined and&#xD;
                       surrounded by aerated lung&#xD;
&#xD;
               -  Clincal lesions only considered measurable when they are superficial (e.g., skin&#xD;
                  nodules or palpable lymph nodes)&#xD;
&#xD;
               -  Target lesion must not have been exposed to prior radiotherapy unless disease has&#xD;
                  progressed since completion of radiotherapy&#xD;
&#xD;
               -  The following are not considered measurable disease:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis or pulmonis&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No HER2/neu-positive tumors by immunohistochemistry or amplified fluorescence in situ&#xD;
             hybridization unless disease has progressed after trastuzumab (Herceptin®)-containing&#xD;
             therapy alone or with antiestrogen hormonal therapy for metastatic disease OR&#xD;
             trastuzumab is contraindicated&#xD;
&#xD;
          -  Prior breast cancer allowed&#xD;
&#xD;
          -  No prior or active brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  No bleeding diathesis or uncontrolled coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  AST and ALT normal AND alkaline phosphatase ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  AST and ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
               -  AST and ALT ≤ 5 times ULN AND alkaline phosphatase normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  No proteinuria OR&#xD;
&#xD;
          -  Protein &lt; 1 g by 24-hour urine collection&#xD;
&#xD;
          -  No nephrotic syndrome&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure &gt; 160/90 mm Hg on ≥ 2 different&#xD;
             observations ≥ 5 minutes apart)&#xD;
&#xD;
               -  Blood pressure &lt; 140/90 mm Hg on ≥ 3 different observations over ≥ 14 days, for&#xD;
                  patients who recently began or adjusted anti-hypertensive medication&#xD;
&#xD;
          -  No atrial or venous thrombosis within the past month&#xD;
&#xD;
          -  No clinically significant heart disease, including any of the following:&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Symptomatic coronary artery disease&#xD;
&#xD;
               -  Uncontrolled cardiac arrhythmias&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No history of cerebrovascular accident&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No hemoptysis within the past 6 months&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No lack of physical integrity of the upper gastrointestinal tract&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
          -  Able to receive oral medication&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other stage III or IV invasive malignancy requiring treatment within the past 5&#xD;
             years&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No history of allergy or hypersensitivity to study drugs, agents that are chemically&#xD;
             similar to study drugs, or drugs that contain polysorbate 80&#xD;
&#xD;
          -  No prior severe reaction to fluoropyrimidines&#xD;
&#xD;
          -  No known hypersensitivity to fluorouracil&#xD;
&#xD;
          -  No known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No significant medical condition that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy allowed for primary disease&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  More than 6 months since prior taxanes (e.g., docetaxel or paclitaxel)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior antiestrogen hormonal therapy allowed in the adjuvant or metastatic setting&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy to a target lesion&#xD;
&#xD;
               -  Prior single-dose palliative radiotherapy allowed within the past 4 weeks&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior aspirin, anticoagulants, or thrombolytic agents&#xD;
&#xD;
               -  Concurrent low-dose warfarin (1 mg/day) to maintain patency of vascular access&#xD;
                  device allowed&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No concurrent aspirin, anticoagulants, or thrombolytic agents&#xD;
&#xD;
          -  No concurrent participation in another clinical trial involving investigational agents&#xD;
             or procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edith A. Perez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol. 2010 Feb;21(2):269-274. doi: 10.1093/annonc/mdp512. Epub 2009 Nov 9.</citation>
    <PMID>19901014</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

